The Health Resources and Services Administration’s proposed rule that would establish an administrative dispute resolution process for the 340B Drug Pricing Program “is an important first step for 340B hospitals and clinics that have been overcharged for drugs purchased through the program,” but there are several areas in which the rule could be amended, AHA said today. Specifically, the AHA urged HRSA to develop a “fast-track process” to provide 340B hospitals and other covered entities access to 340B drug ceiling prices, which “would help ensure a level-playing field in the dispute resolution process,” AHA Executive Vice President Tom Nickels said in a comment letter on the proposed rule. Among other proposals, AHA also commented on the ADR panel composition and decisions; information requests; and claims initiation and consolidation.

Related News Articles

Headline
The Medicare Payment Advisory Commission Friday released its March report to Congress.
Perspective
As our country works to expand health coverage and improve access to care, “Medicare for All” is getting a lot of attention. There are many different flavors…
Headline
Legislative proposals for a Medicare public option could negatively affect patient access to care and significantly reduce payments to hospitals, AHA Executive…
Headline
Creating a government-run, Medicare-like option on the individual health insurance exchanges could negatively affect patient access to care and reduce hospital…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing on the president’s fiscal year 2020 budget request for the Department of Health and…
Headline
President Trump today submitted to Congress his budget request for fiscal year 2020.